XML 66 R12.htm IDEA: XBRL DOCUMENT v2.4.1.9
Fair Value
12 Months Ended
Dec. 31, 2014
Fair Value  
Fair Value
5. Fair Value

 

Fair Value Measurements

 

As defined in ASC 820 “Fair Value Measurements and Disclosures” (“ASC 820”), fair value is based on the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. In order to increase consistency and comparability in fair value measurements, ASC 820 establishes a fair value hierarchy that prioritizes observable and unobservable inputs used to measure fair value into three broad levels, which are described below:

 

· Level 1: Quoted prices (unadjusted) in active markets that are accessible at the measurement date for assets or liabilities. The fair value hierarchy gives the highest priority to Level 1 inputs.
     
· Level 2: Inputs other than quoted prices within Level 1 that are observable for the asset or liability, either directly or indirectly.
     
· Level 3: Unobservable inputs that are used when little or no market data is available. The fair value hierarchy gives the lowest priority to Level 3 inputs.

 

In determining fair value, the Company utilizes valuation techniques that maximize the use of observable inputs and minimize the use of unobservable inputs to the extent possible as well as considering counterparty credit risk in its measurement of fair value.

 

The fair value of the Company’s financial assets and liabilities that are measured on a recurring basis were determined using the following inputs as of December 31, 2013 (in $000s):

 

    Level 1     Level 2     Level 3     Total  
                         
ASSETS                                
Cash equivalents   $ 26,476     $     $     $ 26,476  
Financial instrument associated with stock purchase agreement           397             397  
Total assets   $ 26,476     $ 397     $     $ 26,873  
                                 
LIABILITIES                                
Other liabilities measured at fair value:                                
Scottish Enterprise agreement                 20       20  
Other liabilities measured at fair value                 20       20  
Total liabilities   $     $     $ 20     $ 20  

 

The fair value of the Company’s financial assets and liabilities that are measured on a recurring basis were determined using the following inputs as of December 31, 2014 (in $000s):

 

    Level 1     Level 2     Level 3     Total  
ASSETS                                
Cash equivalents   $ 18,319     $     $     $ 18,319  
Financial instrument associated with stock purchase agreement           51             51  
Total assets   $ 18,319     $ 51     $     $ 18,370  

 

The following table reconciles the beginning and ending balances of Level 3 inputs for the year ended December 31, 2014 (in $000s):

 

    Level 3  
Balance as of December 31, 2013     20  
Change in valuation of Scottish Enterprise agreement     (20 )
Balance as of December 31, 2014      

 

Financial Instrument Associated with Stock Purchase Agreement

 

On November 14, 2013, the Company entered into a common stock purchase agreement with Aspire Capital Fund, LLC (“Aspire”) (the “Purchase Agreement”) under which Aspire purchased 511,509 shares of common stock for an aggregate purchase price of $2.0 million and committed to purchase up to an additional 3,042,038 shares from time to time as directed by the Company over the next two years at prices derived from the market prices on or near the date of each sale (see Note 10 – Stockholders’ Equity).

 

The Company has accounted for the right to sell additional shares under the Purchase Agreement based on the guidance of ASC 815 “Derivative Financial Instruments” (“ASC 815”), which requires the instrument to be measured at fair value with changes in fair value reported in earnings each reporting period until the agreement is exhausted or expired. The instrument had a fair value of $0.5 million at the date of the transaction and a fair value of $0.4 million and $0.1 million as of December 31, 2013 and December 31, 2014, respectively. The $0.3 million decrease in the fair value of the Purchase Agreement during the year ended December 31, 2014 was recognized as a loss in the consolidated statements of operations. The primary inputs used to determine fair value are the price of the Company’s common stock, the remaining term, and aggregate share purchases on the measurement date.

 

Liabilities Measured at Fair Value

 

Scottish Enterprise Agreement

 

On June 22, 2009, the Company amended an agreement with Scottish Enterprise (“SE”) (the “Amendment”) pursuant to which, if the Company failed to maintain minimum staff levels before July 1, 2014 without SE’s prior consent, the Company would have been obligated to pay up to £4 million to SE, calculated as a maximum of £4 million (approximately $6.5 million at December 31, 2013) less the market value of the shares held by SE at the time staffing levels in Scotland fell below the prescribed minimum levels. The staffing levels did not fall below the minimum level before July 1, 2014 and the Company is no longer liable to make any payments under the Amendment.

 

This arrangement was accounted for as a liability under ASC Topic 480 “Distinguishing Liabilities from Equity” (“ASC 480”), and is measured at fair value. Changes in fair value are recognized in earnings. Due to the nature of the associated contingency and the likelihood of occurrence, the Company concluded the fair value of this liability was approximately $20,000 at December 31, 2013. The most significant inputs in estimating the fair value of this liability were the probabilities that staffing levels would fall below the prescribed minimum and that the Company would be unable or unwilling to replace such employees within the prescribed time period. At December 31, 2013, the Company used a scenario analysis model to arrive at the fair value of the Scottish Enterprise Agreement and assumed a 30% probability of falling below a minimum staffing level and a 1% probability that the occurrence of such an event would not be cured within the prescribed time period. At December 31, 2014, the Company had no further liability under the agreement and the fair value of the liability was $0. Changes in the value of this liability have been recorded in the consolidated statement of operations.